Listed by the USPTO as JUEDES, AMY E
Tech Center 1600 • Art Units: 1644 1675
This examiner grants 45% of resolved cases
JUEDES, AMY E is assigned to Tech Center 1600 and Art Unit 1644. The profile contains 926 resolved cases and a 44.7% allowance rate. Allowance occurred in less than half of the recorded cases, making careful initial claim drafting and focused responses important elements of prosecution planning.
The interview lift is 41.9%, indicating a strong positive association between interviews and allowance in this profile. Practitioners may find direct examiner discussion especially relevant when written amendments leave claim interpretation or technical distinctions unresolved. The median time to allowance is 1388 days, pointing to a lengthy observed path to allowance. The leading companies are The Trustees of the University of Pennsylvania, Sloan-Kettering Institute for Cancer Research, and Charité - Universitätsmedizin Berlin. The listed firms are FOLEY & LARDNER LLP, Knobbe, Martens, Olson & Bear, LLP, and pH IP Law.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18037514 | BOVINE ANTIBODY VARIANTS | Non-Final OA | Zoetis Services LLC |
| 18587251 | METHODS OF TREATING TAU PATHOLOGIES | Non-Final OA | Genentech, Inc. |
| 18281471 | ENGINEERED IMMUNE CELLS AND USES THEREOF | Non-Final OA | The Johns Hopkins University |
| 18021687 | B-CELL BASED IMMUNOTHERAPY FOR THE TREATMENT OF GLIOBLASTOMA AND OTHER CANCERS | Final Rejection | Northwestern University |
| 18559146 | INHIBITORY CHIMERIC ANTIGEN RECEPTOR PREVENTS ON-TARGET OFF-TUMOR EFFECTS OF ADOPTIVE CELL THERAPY | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17864389 | COMPOSITIONS AND METHODS FOR TARGETED PROTEIN STABILIZATION BY REDIRECTING ENDOGENOUS DEUBIQUITINASES | Final Rejection | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK |
| 18625699 | METHODS FOR USING ENRICHED EXOSOMES AS A PLATFORM FOR MONITORING ORGAN STATUS | Final Rejection | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 17735624 | COMPOSITIONS AND METHODS FOR REGULATING CAR T CELLS | Final Rejection | The Trustees of the University of Pennsylvania |
| 17576597 | DENDRITIC CELL IMMUNOTHERAPY | Non-Final OA | BAYLOR COLLEGE OF MEDICINE |
| 14437902 | METHOD FOR PREPARATION OF A HIGH CONCENTRATION LIQUID FORMULATION OF AN ANTIBODY | Final Rejection | TAKEDA PHARMACEUTICAL COMPANY LIMITED |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy44.7% of resolved applications examined by Amy E Juedes were allowed (926 resolved cases), compared with 35.9% across Art Unit 1644 over the last five years.
This examiner's interview lift is +41.9 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Amy E Juedes took 1,388 days on average from filing to allowance.
Amy E Juedes examines applications in Art Unit 1644 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
